東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Anti-estrogen therapy and breast can...

Trebley, Joseph P.

FindBook

Google Book

Amazon

博客來

Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance./
作者:	Trebley, Joseph P.
面頁冊數:	117 p.
附註:	Source: Dissertation Abstracts International, Volume: 68-02, Section: B, page: 0909.
Contained By:	Dissertation Abstracts International68-02B.
標題:	Health Sciences, Pharmacology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3251708

Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance.
Trebley, Joseph P.

Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance. - 117 p.

Source: Dissertation Abstracts International, Volume: 68-02, Section: B, page: 0909.

Thesis (Ph.D.)--Purdue University, 2006.

Anti-estrogen therapies like tamoxifen are the most successful breast cancer treatments to date. However, molecular mechanisms responsible for decreased efficacy and the evolution of resistance are poorly characterized. 4-hydroxytamoxifen (OHT) is a tamoxifen metabolite with much higher binding affinity to the estrogen receptor (ER). For this reason, many of the anti-estrogenic effects of tamoxifen are attributed to OHT and not the parent drug. Others have shown that additional metabolites of tamoxifen are present in sera at much higher levels than OHT. The concentration of at least one of these metabolites is lowered by genetic variations in cytochrome P450 CYP2D6 and coadministration of anti-depression drugs that are potent inhibitors of the same. We report here a facile three step synthetic method through which 4-hydroxylated tamoxifen metabolites can be synthesized. Through these synthetic means, we confirm that N-desmethyl-4-hydroxytamoxifen (Endoxifen) is the unknown metabolite affected by variations in and inhibitors of CYP2D6. Endoxifen binds to ER with similar affinity as OHT and inhibits estrogen-dependent ERE-driven transcription as well as cell proliferation with similar potency and efficacy as OHT. We conclude that endoxifen is not only present at higher concentrations in sera than OHT but also equally effective as an anti-estrogen. Therefore, endoxifen likely plays an important role in the anti-estrogen effects of tamoxifen, and genetic variations or drug interactions may be responsible for decreased efficacy of tamoxifen therapy.Subjects--Topical Terms:

1017717
Health Sciences, Pharmacology.

Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance.
LDR:03368nmm 2200289 4500 001 1829142
005 20071106080136.5
008 130610s2006 eng d
035 $a (UMI)AAI3251708
035 $a AAI3251708
040 $a UMI $c UMI
100 1 $a Trebley, Joseph P. $3 1918011
245 1 0 $a Anti-estrogen therapy and breast cancer: Molecular mechanisms of efficacy and resistance.
300 $a 117 p.
500 $a Source: Dissertation Abstracts International, Volume: 68-02, Section: B, page: 0909.
500 $a Adviser: Ross V. Weatherman.
502 $a Thesis (Ph.D.)--Purdue University, 2006.
520 $a Anti-estrogen therapies like tamoxifen are the most successful breast cancer treatments to date. However, molecular mechanisms responsible for decreased efficacy and the evolution of resistance are poorly characterized. 4-hydroxytamoxifen (OHT) is a tamoxifen metabolite with much higher binding affinity to the estrogen receptor (ER). For this reason, many of the anti-estrogenic effects of tamoxifen are attributed to OHT and not the parent drug. Others have shown that additional metabolites of tamoxifen are present in sera at much higher levels than OHT. The concentration of at least one of these metabolites is lowered by genetic variations in cytochrome P450 CYP2D6 and coadministration of anti-depression drugs that are potent inhibitors of the same. We report here a facile three step synthetic method through which 4-hydroxylated tamoxifen metabolites can be synthesized. Through these synthetic means, we confirm that N-desmethyl-4-hydroxytamoxifen (Endoxifen) is the unknown metabolite affected by variations in and inhibitors of CYP2D6. Endoxifen binds to ER with similar affinity as OHT and inhibits estrogen-dependent ERE-driven transcription as well as cell proliferation with similar potency and efficacy as OHT. We conclude that endoxifen is not only present at higher concentrations in sera than OHT but also equally effective as an anti-estrogen. Therefore, endoxifen likely plays an important role in the anti-estrogen effects of tamoxifen, and genetic variations or drug interactions may be responsible for decreased efficacy of tamoxifen therapy.
520 $a Phases of anti-estrogen resistance are defined by a tumor's response to ligands. One type of resistance is identified by a tumor response profile where anti-estrogens like tamoxifen stimulate growth whereas estradiol represses the same. Serum response factor is a growth promoting transcription factor activated by growth factor signaling pathways partially responsible for tamoxifen resistance and known to cross-talk with ER. Here we report that in MCF-7 cells estradiol activates SRF-dependent transcription whereas all anti-estrogens have little to no effect. However, in SKBR3 cells transiently transfected with ER, raloxifene, tamoxifen, and fulvestrant activate SRF activity. That activity is repressed by both estradiol and anti-estrogen GW-7604. These data suggest that ER-modulation of SRF activity could play a role in changes in ligand response in different cellular contexts.
590 $a School code: 0183.
650 4 $a Health Sciences, Pharmacology. $3 1017717
650 4 $a Health Sciences, Medicine and Surgery. $3 1017756
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0419
690 $a 0564
690 $a 0992
710 2 0 $a Purdue University. $3 1017663
773 0 $t Dissertation Abstracts International $g 68-02B.
790 1 0 $a Weatherman, Ross V., $e advisor
790 $a 0183
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3251708